Pacira Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as Flexion Therapeutics, Inc. (to 2022)
2
Ending by 2030
Aug 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 21, 2027The maintenance fee for Corticosteroids for the Treatment of Joint Pain (US 10,624,905) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
- Aug 25 US 12,714,755 Effective Dosages of an Adenoviral-Based Biological Delivery and Expression System for Use in the Treatment of Osteoarthritis in Humans, and Compositions Comprising the Same
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,450,358 | Enantiomers of Spiro-Oxindole Compounds and Their Uses as Therapeutic Agents In force · High confidence | In force | High confidence | |
| US 9,504,671 | Pharmaceutical Compositions of Spiro-Oxindole Compound for Topical Administration and Their Use as Therapeutic Agents In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 8,445,696 | Synthetic Methods for Spiro-Oxindole Compounds In force · High confidence | In force | High confidence | |
| US 8,828,440 | Corticosteroids for the Treatment of Joint Pain In force · Medium confidence | In force | Medium confidence | |
| US 9,555,047 | Corticosteroids for the Treatment of Joint Pain In force · Medium confidence | In force | Medium confidence | |
| US 9,555,048 | Corticosteroids for the Treatment of Joint Pain In force · Medium confidence | In force | Medium confidence | |
| US 9,949,987 | Corticosteroids for the Treatment of Joint Pain In force · Medium confidence | In force | Medium confidence | |
| US 10,624,905 | Corticosteroids for the Treatment of Joint Pain In force · Medium confidence | In force | Medium confidence | |
| US 9,487,535 | Asymmetric Syntheses for Spiro-Oxindole Compounds Useful as Therapeutic Agents In force · High confidence | In force | High confidence | |
| US 9,682,033 | Methods of Treating Postherpetic Neuralgia with a Topical Formulation of a Spiro-Oxindole Compound In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending